Hopp til innhold

Get alerts of updates about «Treatment for localized prostate cancer: a rapid review for patient decision aid (update)»

How often would you like to receive alerts from fhi.no? (This affects all your alerts)
Do you also want alerts about:

The email address you register will only be used to send you these alerts. You can cancel your alerts and delete your email address at any time by following the link in the alerts you receive.
Read more about the privacy policy for fhi.no

You have subscribed to alerts about:

  • Treatment for localized prostate cancer: a rapid review for patient decision aid (update)

Systematic review

Treatment for localized prostate cancer: a rapid review for patient decision aid (update)

Published

In this rapid review, the purpose was to update the knowledge base for the joint selection tool for the treatment of prostate cancer without spread.

Rapportens forside

In this rapid review, the purpose was to update the knowledge base for the joint selection tool for the treatment of prostate cancer without spread.


Downloadable as PDF. In Norwegian. English key messages.

About this publication

  • Year: 2023
  • By: Norwegian Institute of Public Health
  • Authors Klem HE, Evensen LH.
  • ISBN (digital): 978-82-8406-330-0

Key message

Prostate cancer is the second most frequently diagnosed cancer among men worldwide. Although the incidence of prostate cancer is high, the mortality rate is relatively low. The term localised prostate cancer ranges from low-risk patients who are not in need of treatment, to high-risk patients who need treatment. We included one systematic review on the effects of surgery compared to active surveillance and observation in prostate cancer without metastasis.

The results from our summary showed that radical prostatectomy likely:

  • reduces the risk of death, disease progression and metastatic disease, compared to observation
  • results in little or no difference in the risk of death and in health-related quality of life, compared to active surveillance
  • reduces the risk of disease progression and metastatic disease, compared to active surveillance
  • results in no difference in bowel function, compared to active surveillance